Table 3 Induction therapy.
From: Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer
Characteristic | |
|---|---|
Patients | 13 |
Treatment cycles, total | 99 |
Treatment cycles, median (range) | 6 (5–13) |
Cycles containing | |
FOLFIRINOX, median (range) | 5 (1–13) |
FOLFOX, median (range) | 4 (2–9) |
Cycles with | |
Dose reduction | 21 (21%) |
Treatment delay ≥1 week | 23 (23%) |
Treatment time, median (range) | 19.9 weeks (12.3–27.3) |
